A Phase 2 Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of TD-9855 in Patients With Fibromyalgia (FM)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of TD-9855 in Patients With Fibromyalgia (FM)
The purpose of this study study is to determine whether TD-9855 is effective in treating patients with fibromyalgia.
Inclusion Criteria:
• American College of Rheumatology (ACR) Diagnostic Criteria for Fibromyalgia (FM)
Informed consent
18 to 65 years of age
Discontinue therapy with adrenergic-acting drugs, and certain other medications
Exclusion Criteria: